Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma

Trial Profile

Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs AV-GBM-1 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors AiVita Biomedical
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 1 Feb 2025 to 1 Apr 2023.
    • 09 Mar 2018 Planned primary completion date changed from 1 Feb 2023 to 1 Oct 2020.
    • 09 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top